Comparing GLP-1RA with basal insulin, a GLM class recently observed not to be associated with pancreatic cancer risk,26 ensures comparison of patients who require second-line therapy and avoids their comparison with patients requiring less intensive therapy for their diabetes. This evidence concerns the gene INS and pancreatic neoplasm.